Skip to Content

Notice

A Public Health Action Plan To Combat Antimicrobial Resistance (Part I: Domestic Issues): Meeting for Public Comment on the Antimicrobial Resistance Interagency Task Force Annual Report

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH) announce an open meeting concerning antimicrobial resistance.

Name: A Public Health Action Plan to Combat Antimicrobial Resistance (Part I: Domestic Issues): Meeting for Public Comment on the Antimicrobial Resistance Interagency Task Force Annual Report.

Time and Date: 10 a.m.-5 p.m., June 26, 2002.

Place: Holiday Inn Select, Versailles Ballroom, 8120 Wisconsin Avenue, Bethesda, Maryland, 20814. (Toll-Free: 1-877-888-3001; Tel: 1-301-652-2000; Fax: 1-301-652-4525).

Status: Open to the public, limited only by the space available.

Purpose: To present the first annual report of progress by Federal agencies in accomplishing activities outlined in A Public Health Action Plan to Combat Antimicrobial Resistance (Part I: Domestic Issues) and solicit comments from the public regarding the annual report. The Action Plan serves as a blueprint for activities of Federal agencies to address antimicrobial resistance. The focus of the plan is on domestic issues.

Matters To Be Discussed: The agenda will consist of welcome, introductory comments, followed by discussion of each focus area in sequential plenary sessions lasting about 75 minutes each. The four focus areas are: Surveillance, Prevention and Control, Research, and Product Development. Session leaders will give a 10 to 15 minute overview at the beginning of each session, then open the meeting for general discussion.

Comments and suggestions from the public for Federal agencies related to each of the focus areas will be taken under advisement by the Antimicrobial Resistance Interagency Task Force. The agenda does not include development of consensus positions, guidelines, or discussions or endorsement of specific commercial products.

The Action Plan, Annual Report, and meeting agenda are available at http://www.cdc.gov/​drugresistance. The public meeting is sponsored by the CDC, FDA, and NIH in collaboration with seven other Federal agencies and departments involved in developing and writing A Public Health Action Plan to Combat Antimicrobial Resistance (Part I: Domestic Issues).

Agenda items are subject to change as priorities dictate.

Limited time will be available for oral questions, comments, and suggestions from the public. Depending on the number wishing to comment, a time limit of three minutes may be imposed. In the interest of time, visual aids will not be permitted, although written material may be submitted for subsequent review by the Task Force. Written comments and suggestions from the public are encouraged and should be received by the contact person or email listed below prior to the opening of the meeting or no later than the end of July 2002. Start Printed Page 30932

Persons anticipating attending the meeting are requested to send written notification by June 22, 2002, including name, organization (if applicable), address, phone, fax, and e-mail address.

Start Further Info

CONTACT PERSON FOR MORE INFORMATION:

Vickie Garrett, Antimicrobial Resistance, Office of the Director, NCID, CDC, Mailstop C-12, 1600 Clifton Road, NE, Atlanta, GA 30333; telephone 404-639-2603; fax 404-639-4197; or e-mail aractionplan@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Start Signature

Dated: April 11, 2002.

Alvin Hall,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

Dated: April 16, 2002.

Ruth L. Kirschstein,

Acting Director, National Institutes of Health.

Dated: April 26, 2002.

Margaret M. Dotzel,

Associate Commissioner for Policy.

End Signature End Further Info End Preamble

[FR Doc. 02-11361 Filed 5-7-02; 8:45 am]

BILLING CODE 4163-18-P